Predictors of drug survival of biologic therapies in psoriasis patients
| Autor: | Ozge Zorlu, Deniz Sigirli, Kenan Aydogan, Hayriye Sarıcaoğlu, Emel Bülbül Başkan, Ferah Budak, Serkan Yazici, Lacin Cevhertas |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Drug medicine.medical_specialty media_common.quotation_subject Dermatology Etanercept 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Internal medicine Psoriasis medicine Humans Retrospective Studies media_common 030203 arthritis & rheumatology business.industry Biologic therapies Adalimumab medicine.disease Infliximab Biological Therapy Drug survival Pharmaceutical Preparations Tumor Necrosis Factor Inhibitors Tumor necrosis factor alpha business |
| Zdroj: | Journal of Dermatological Treatment. 33:437-442 |
| ISSN: | 1471-1753 0954-6634 |
| Popis: | We aimed to investigate the clinical, immunological, and genetic factors affecting the response to anti-TNFα (tumor necrosis factor-α) and interleukin-12/23 therapies and drug survivals.A total of 180 patients were divided into two groups: 89 patients who used at least two biologic agents, with the initial biologic agent used less than 12 months (group A), and 91 biologic-naive patients who have been receiving a single biologic agent for more than 12 months (group B). ELISA (enzyme-linked immunosorbent assay) was used to analyze anti-drug antibodies (ADAs) in blood samples. Clinical data of the patients were retrospectively analyzed. HLA-SSO (sequence-specific oligonucleotide) Typing Kits were used for HLA-C typing. IBM SPSS v.21 was used for statistical analysis.RAlthough our study is retrospective of a relatively low number of patients, this is a preliminary study focusing on two different patient populations based on therapy response. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|